| Status: Medicine does not meet criteria for AWMSG assessment | |
Excluded from appraisal by AWMSG as meets exclusion criteria 4. See AWMSG criteria for appraising a medicine (PDF, 430Kb) for information. |
|
Medicine details |
|
| Medicine name | darunavir (Prezista®) |
| Formulation | 800 mg film-coated tablet |
| Reference number | 1795 |
| Indication | In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART) naïve adults and in ART-experienced adult HIV-1 patients with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 106/l. In deciding to initiate treatment with Prezista in such ART-experienced adults genotypic testing should guide the use of Prezista. |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Medicine does not meet criteria for AWMSG assessment |
| Date of issue | 21/12/2012 |